CN Bio: Funding, Investors & Team (Oct 2026)
CN Bio Innovations, previously known as Zyoxel Ltd, is a subsidiary of Hong Kong-based CN Innovations Holdings Limited (CNI). The company specializes in creating organ-on-a-chip platforms to test and develop treatments for severe human ailments. One of CN Bio's primary organ-on-chip models is a comprehensive hepatitis B (HBV) viral lifecycle model, named Quantum-B, which involves the cultivation of primary human hepatocytes in their LiverChip platform. This model is currently being utilized in drug discovery partnerships with various prominent pharmaceutical and biotech companies. CN Bio collaborates closely with pioneering academics in bio-engineering and has received grants from respected organizations like the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board. The company's ongoing development of advanced organ-on-chips aims to expedite the arrival of groundbreaking therapies to improve the lives of millions worldwide.
CN Bio has raised $21.0M across 1 funding round on record, the most recent a Series B of $21.0M announced in Apr 2024.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
CN Bio Company Profile and Key Stats
Latest funding round on record: Apr 2024.
CN Bio Funding Rounds
CN Bio Founders and Leadership Team
No contact details are on record for this team yet.
CN Bio Funding Compared to Other Biotechnology Startups
CN Bio's latest round of $21.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like CN Bio in Biotechnology and Welwyn Garden City
Companies Similar to CN Bio
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
CN Bio Funding FAQs
What does CN Bio do?
CN Bio Innovations, previously known as Zyoxel Ltd, is a subsidiary of Hong Kong-based CN Innovations Holdings Limited (CNI). The company specializes in creating organ-on-a-chip platforms to test and develop treatments for severe human ailments. One of CN Bio's primary organ-on-chip models is a comprehensive hepatitis B (HBV) viral lifecycle model, named Quantum-B, which involves the cultivation of primary human hepatocytes in their LiverChip platform. This model is currently being utilized in drug discovery partnerships with various prominent pharmaceutical and biotech companies. CN Bio collaborates closely with pioneering academics in bio-engineering and has received grants from respected organizations like the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board. The company's ongoing development of advanced organ-on-chips aims to expedite the arrival of groundbreaking therapies to improve the lives of millions worldwide.
How much funding has CN Bio raised?
CN Bio has raised $21.0M across 1 round on record. The most recent is a Series B of $21.0M announced in Apr 2024.
When did CN Bio last raise funding?
CN Bio's most recent funding round on record is a Series B of $21.0M, announced in Apr 2024.
Who founded CN Bio?
FundedIQ lists Linda Griffith (Founder) at CN Bio.
Where is CN Bio headquartered?
CN Bio is based in Welwyn Garden City, Hertford, United Kingdom.
How many employees does CN Bio have?
CN Bio is in the 101-250 employee band.
How does CN Bio's funding compare to other Biotechnology startups?
CN Bio's latest round of $21.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's CN Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CN Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.